SLC31A1 and central nervous system cancer: We found that the SLC31A1 expression level is lower in the IDH mutation group and 1p/19q codeletion group, which means that the SLC31A1 might influence the outcomes of glioma patients by influencing IDH mutation and 1p/19q codeletion.